Clinical decision making in postmastectomy radiotherapy in node negative breast cancer

Rodrigo Barrientos, Suraj Samtani, Michael Frelinghuysen, Camilo Sotomayor, Juan Guillermo Gormaz, Mauricio Burotto*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


For decades, postmastectomy radiotherapy (PMRT) has been recommended for node positive [N(+)] breast cancer patients; nevertheless, the beneficial effect of PMRT for treatment of node negative [N(-)] disease remains under discussion. Nowadays, the biology of breast cancer and the risk factors (RFs) for locoregional failure (LRF) must be included in the decision on whether or not to carry out PMRT. For these reasons, the present review aims to evaluate the rationale use of PMRT in N(-) patients and discuss which subgroups may further benefit from the treatment in present times where the decision must be personalised, according to the RFs of locoregional recurrence (LRR). To perform the analysis, we ponder that LRR of over 10% should be considered unacceptable due to the fact that LRRs generate great morbidity in patients. For this purpose, we consider that routine RT in these patients is not recommended, although there are subgroups of patients with high LRR, in which PMRT could be beneficial.

Original languageEnglish
Article number874
StatePublished - 26 Sep 2018
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2018 the authors.


  • Breast cancer radiotherapy
  • Node negative breast cancer
  • Postmastectomy radiotherapy


Dive into the research topics of 'Clinical decision making in postmastectomy radiotherapy in node negative breast cancer'. Together they form a unique fingerprint.

Cite this